Hypoglycaemia is characterised by abnormally low levels of blood sugar. Credit: Proxima Studio/Shutterstock.com.

Arecor Therapeutics’ subsidiary Tetris Pharma has announced a commercialisation agreement with Goodlife for Ogluo.

Under the exclusive agreement, Goodlife will act as sole partner to import, market and distribute Ogluo in the BeNeLux region.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ogluo is a ready-to-use, ambiently stored glucagon preparation in an auto-injector for patients in the licensed indication with diabetes and severe hypoglycaemia.

The National Healthcare Institute of the Netherlands, Zorginstiuut Nederland, granted approval for Ogluo at the requested price on List 1B.

Goodlife is expected to launch Ogluo in the country during the first half of next year.

See Also:

Arecor CEO Sarah Howell said: “Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the company’s continued rollout of Ogluo and its market adoption in the Benelux region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The upcoming launch in the Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned ongoing pan-European commercial rollout for this important product.”

Ogluo received marketing authorisation from the European Commission in February 2021.

Hypoglycaemia, which is characterised by abnormally low levels of blood sugar, is a serious complication of diabetes and affects individuals with diabetes on insulin treatment, in particular.

Goodlife managing director Koen Perenboom said: “With more than a quarter of a million people living with insulin-treated diabetes and at risk of severe hypoglycaemia in the Netherlands, Ogluo is an important treatment option for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events.”